Product nameAnti-SPTLC1 antibody
See all SPTLC1 primary antibodies
DescriptionRabbit polyclonal to SPTLC1
Tested applicationsSuitable for: WB, IPmore details
Species reactivityReacts with: Mouse, Human
Predicted to work with: Rabbit, Horse, Chicken, Guinea pig, Cow, Pig, Chimpanzee, Cynomolgus monkey, Rhesus monkey
- HeLa, 293T, Jurkat and NIH3T3 whole cell lysates.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituents: 0.1% BSA, 99% Tris buffered saline
Concentration information loading...
PurityImmunogen affinity purified
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipid metabolism
Our Abpromise guarantee covers the use of ab176706 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000 - 1/10000. Predicted molecular weight: 53 kDa.|
|IP||Use at 2-10 µg/mg of lysate.|
FunctionSerine palmitoyltransferase (SPT). The heterodimer formed with LCB2 (SPTLC2 or SPTLC3) constitutes the catalytic core. The composition of the serine palmitoyltransferase (SPT) complex determines the substrate preference. The SPTLC1-SPTLC2-SSSPTA complex shows a strong preference for C16-CoA substrate, while the SPTLC1-SPTLC3-SSSPTA isozyme uses both C14-CoA and C16-CoA as substrates, with a slight preference for C14-CoA. The SPTLC1-SPTLC2-SSSPTB complex shows a strong preference for C18-CoA substrate, while the SPTLC1-SPTLC3-SSSPTB isozyme displays an ability to use a broader range of acyl-CoAs, without apparent preference.
Tissue specificityWidely expressed. Not detected in small intestine.
PathwayLipid metabolism; sphingolipid metabolism.
Involvement in diseaseDefects in SPTLC1 are the cause of hereditary sensory and autonomic neuropathy type 1A (HSAN1A) [MIM:162400]. The hereditary sensory and autonomic neuropathies are a genetically and clinically heterogeneous group of disorders characterized by degeneration of dorsal root and autonomic ganglion cells, and by sensory and/or autonomic abnormalities. HSAN1A is an autosomal dominant axonal neuropathy with onset in the second or third decades. Initial symptoms are loss of pain, touch, heat, and cold sensation over the feet, followed by distal muscle wasting and weakness. Loss of pain sensation leads to chronic skin ulcers and distal amputations.
Sequence similaritiesBelongs to the class-II pyridoxal-phosphate-dependent aminotransferase family.
Cellular localizationEndoplasmic reticulum membrane.
- Information by UniProt
- HSAN antibody
- HSAN1 antibody
- HSN1 antibody
All lanes : Anti-SPTLC1 antibody (ab176706) at 0.04 µg/ml
Lane 1 : HeLa whole cell lysate at 50 µg
Lane 2 : HeLa whole cell lysate at 15 µg
Lane 3 : 293T whole cell lysate at 50 µg
Lane 4 : Jurkat whole cell lysate at 50 µg
Lane 5 : NIH3T3 whole cell lysate at 50 µg
Developed using the ECL technique.
Predicted band size: 53 kDa
Exposure time: 30 seconds
ab176706 at 0.4 µg/ml detecting SPTLC1 in HeLa whole cell lysate by WB following IP.
Lane 1: ab176706 at 6 µg/mg of lysate
Lane 2: IP with an antibody which recognizes an downstream epitope of SPTLC1.
Lane 3: Control IgG.
In each case, 1 mg of lysate was used for IP and 20% of the IP was loaded.
Detection: Chemiluminescence with an exposure time of 10 seconds.